anti-L1CAM antibody radionuclide conjugate (CIS Pharma AG/Paul Scherrer Institut/KU Leuven)

N/A

Report date: 2025/06/11 11:07:03

Base Information

Drug Nameanti-L1CAM antibody radionuclide conjugate (CIS Pharma AG/Paul Scherrer Institut/KU Leuven)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionNeural cell adhesion molecule L1 inhibitors
TargetsNeural cell adhesion molecule L1
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumSwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPaul Scherrer Institut
China Registration ClassN/A

Develop Information

Active CompaniesCIS Pharma AGPaul Scherrer InstitutKu Leuven
Inactive CompaniesN/A
Active IndicationsOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A